Tech Company Financing Transactions
Amplimmune Funding Round
Amplimmune closed a $20 million Series A funding round on 4/13/2007. Investors included InterWest Partners and The Wellcome Trust.
Transaction Overview
Company Name
Announced On
4/13/2007
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
InterWest Partners (James Campbell)
The Wellcome Trust (Julie Eskay-Eagle)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
45 W Watkins Mill Rd Suite A
Gaithersburg, MD 20878
USA
Gaithersburg, MD 20878
USA
Phone
Website
Email Address
Not Recorded
Overview
Founded in 2007 and headquartered in Gaithersburg, MD, Amplimmune is focused on developing novel co-stimulatory/co-inhibitory molecules that rebalance the immune system and are intended for treating cancer, autoimmune disease, infectious disease, and transplantation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Richman
Browse more venture capital transactions:
Prev: 4/13/2007: Nanochip venture capital transaction
Next: 4/16/2007: Exinda Networks venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. All VC database entries reported here come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs